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Prevention of Perinatal Group B Streptococcal
Disease: 
A Public Health Perspective
Summary
Group B streptococcus is a leading cause of serious neonatal infection. Most
neonatal GBS infections can be prevented through the use of intrapartum an-
timicrobial prophylaxis in women who are at increased risk for transmitting the
infection to their newborns. However, despite clinical trials that demonstrate the
effectiveness of intrapartum antibiotic prophylaxis, prevention strategies have
not been implemented widely or consistently, and the incidence of neonatal
GBS disease has not declined. To promote a coordinated approach to prevention
among obstetric- and pediatric-care practitioners and among supporting clinical
microbiology laboratory personnel, CDC has developed prevention guidelines in
conjunction with experts from relevant disciplines and with representatives of
the American College of Obstetricians and Gynecologists, the American Acad-
emy of Pediatrics, and other professional organizations. This report provides the
epidemiologic basis for prevention protocols, summarizes results of clinical
trials demonstrating the efficacy of intrapartum antimicrobial agents, examines
limitations of different approaches to prevention, and presents guidelines for
the prevention of GBS disease. CDC recommends use of one of two prevention
strategies. In the first strategy, intrapartum antibiotic prophylaxis is offered to
women identified as GBS carriers through prenatal screening cultures collected
at 35–37 weeks’ gestation and to women who develop premature onset of labor
or rupture of membranes at <37 weeks’ gestation. In the second strategy, intra-
partum antibiotic prophylaxis is provided to women who develop one or more
risk conditions at the time of labor or membrane rupture.  Issues addressed by
these prevention guidelines include the following: the appropriate clinical and
laboratory methods required for prenatal screening programs designed to iden-
tify GBS carriers; risk conditions that indicate the need for intrapartum
antibiotics; management of newborns whose mothers receive intrapartum anti-
biotic prophylaxis for GBS disease; and education of prenatal patients regarding
GBS disease and the available prevention policy. These guidelines are intended
for the following groups: a) providers of prenatal, obstetric, and pediatric care;
b) supporting microbiology laboratories, hospital administrators, and managed-
care organizations; c) childbirth educators; d) public health authorities;
e) expectant parents; and f) advocacy groups for expectant parents.
INTRODUCTION
Since its emergence in the 1970s, group B streptococcal (GBS) disease has been
the leading bacterial infection associated with illness and death among newborns in
the United States. Newborns at increased risk for GBS disease are those born to
women who are colonized with GBS in the genital or rectal areas. Colonized women
who experience either a long duration of membrane rupture, premature delivery, or
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intrapartum fever are at particularly high risk for transmitting GBS infection to their
infants during labor and delivery. Infants who have GBS disease can require pro-
longed hospitalization and expensive supportive therapy, and survivors may suffer
permanent disability (e.g., hearing or visual loss or mental retardation).
Many perinatal GBS infections can be prevented through intrapartum antimicrobial
prophylaxis. GBS disease prevention programs require coordinated efforts among
numerous specialties (e.g., providers of prenatal, obstetric, and pediatric care; sup-
porting microbiology laboratories; managed-care organizations; quality assurance
personnel; childbirth educators; and public health authorities).
CDC developed these GBS disease prevention guidelines through critical analysis
of clinical trial data and subsequent review of guidelines by consultants representing
numerous disciplines. In December 1994, a draft version of the guidelines was pub-
lished in the Federal Register. On March 10, 1995, CDC convened a meeting of clinical
experts, public health authorities, representatives from professional organizations,
and patient advocates to further consider these guidelines. The guidelines published
in this report have been reviewed by both the American College of Obstetricians and
Gynecologists and the American Academy of Pediatrics. In addition, this document
provides the epidemiologic basis for prevention protocols, summarizes results of
clinical trials, examines limitations of various approaches to prevention, and presents
prevention guidelines.
BACKGROUND
Group B streptococcus, or Streptococcus agalactiae, is a gram-positive coccus that
causes invasive disease primarily in newborns, pregnant women, and adults with
underlying medical conditions (e.g., diabetes mellitus). In infants, GBS disease is char-
acterized as either early-onset (i.e., occurring in infants <7 days of age) or late-onset
(i.e., occurring in infants ≥7 days of age). Disease in infants usually occurs as bactere-
mia, pneumonia, or meningitis (1 ). Other syndromes (e.g., cellulitis and osteo-
myelitis) also can occur. Approximately 25% of the cases of neonatal GBS disease
occurs in premature infants (2 ).
In pregnant women, GBS infection causes urinary tract infection, amnionitis, en-
dometritis, and wound infection; stillbirths and premature delivery also have been
attributed to GBS (1 ). In nonpregnant adults, skin or soft tissue infection, bacteremia,
genitourinary infection, and pneumonia are the most common manifestations of dis-
ease (2,3 ).
The case-fatality rate for GBS disease is estimated to be 5%–20% for newborns
(1,2,4 ) and 15%–32% (2,3,5 ) for adults. A recent multistate, active surveillance system
in a population of 10 million persons (2 ) demonstrated that 6% of early-onset GBS
infections resulted in death. This case-fatality rate is lower than those reported pre-
viously (1,6 ), particularly the rates of 15%–50% observed in studies from the 1970s
(7–9 ). This reduction in deaths most likely has resulted from improvements in neo-
natal care (10,11 ).
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EPIDEMIOLOGY
Colonization
The gastrointestinal tract is the most likely human reservoir of GBS, with the geni-
tourinary tract the most common site of secondary spread (1 ). Colonization rates can
differ among ethnic groups, geographic locales, and by age; however, rates are similar
for pregnant and nonpregnant women (1,12–14 ). In most populations studied, from
10% to 30% of pregnant women were colonized with GBS in the vaginal or rectal area
(12,13,15,16 ). Of all infants born to colonized parturients, approximately 1%–2% will
develop early-onset invasive disease (1 ).
The isolation rate of GBS from clinical specimens depends on several factors. Cul-
turing specimens from both the anorectum and the vaginal introitus increases the
likelihood of GBS isolation by 5%–27% over vaginal culture alone (15–17 ). The use of
selective media (i.e., broths containing antimicrobial agents to inhibit competing
organisms) is essential because they can increase the yield of screening cultures by as
much as 50% (18,19 ). Appropriate selective broth media—either SBM broth or Lim
broth—are commercially available.
Incidence of Neonatal Disease
Multistate, population-based methods of case-finding have been used to estimate
the incidence of neonatal GBS disease in the United States. Age- and race-adjusted
projections from multistate surveillance suggested that, in 1990, 7,600 episodes (i.e.,
incidence rate of 1.8 per 1,000 live births) and 310 deaths in the United States resulted
from GBS disease among infants ≤90 days of age (2 ). Early-onset infections ac-
counted for approximately 80% of neonatal GBS infections (2 ). Based on data from
early case-series, long-term neurologic sequelae have been estimated to occur in
15%–30% of meningitis survivors (1 ); more recent estimates of the incidence and
costs of sequelae from neonatal GBS disease are not available.
Risk Factors for Perinatal GBS Disease
Results of studies indicate that several obstetric, maternal, and neonatal factors
increase the likelihood that early-onset GBS disease will occur in a newborn (Table 1).
Infants born to women who were identified prenatally as GBS carriers had 29 times
the risk of early-onset disease than did infants born to women whose prenatal cultures
were negative (20 ). In the same study population, deliveries in which prematurity,
longer duration of membrane rupture, or intrapartum fever occurred were approxi-
mately seven times more likely to be complicated by early-onset GBS disease (20 ).
The incidence of GBS disease also is higher among infants born to mothers who
are <20 years of age (21,22 ) or of black race (2,21 ). Other women with increased like-
lihood of delivering an infant who has invasive GBS disease are those with heavy
colonization of GBS in genital cultures (8 ) or with low levels of anti-GBS capsular
antibody (23 ) and women who previously delivered an infant who had GBS disease
(24–26 ). Women with GBS bacteriuria during pregnancy usually are heavily colonized
with GBS and appear to be at increased risk for perinatal transmission (27–30 ).
Although multiple gestation has been suggested as a risk factor for GBS disease
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(31,32 ), only one study indicated increased risk independent of prematurity (31 ).
Recent large studies failed to detect increased risk associated with multiple gestation
(21,22 ). Risk factors identified for neonates include low birth weight and heavy sur-
face colonization with GBS (8,33 ).
Determinants of late-onset GBS disease are not well documented; however, some
evidence suggests that late-onset disease can be acquired through either vertical or
nosocomial transmission (6,34,35 ), although acquisition of disease from community
sources also is possible (14 ).
The role of GBS colonization in maternal infections was recently investigated (36 ).
Factors that independently increased the risk for clinical amnionitis included GBS
colonization, duration of membrane rupture (i.e., >6 hours), duration of internal moni-
toring (i.e., >12 hours), and number of vaginal examinations (i.e., more than six) (36 ).
PREVENTION STRATEGIES
Almost half the cases of invasive GBS disease occurs in newborns (2 ); therefore,
efforts to prevent GBS disease have been concentrated on this group. Research has
focused on either inducing protective immunity in the newborn (active and passive
immunization) or eradicating colonization from the mother and/or newborn (chemo-
prophylaxis).
Immunization
Several studies have indicated that susceptibility to neonatal GBS disease is
caused by a deficiency of maternal anticapsular antibody (23,37 ). Active maternal
immunization may prevent peripartum maternal disease and neonatal disease by
transplacental transfer of protective IgG antibodies (38 ).
TABLE 1. Risk for early-onset group B streptococcal (GBS) disease (20 ), by prenatal















Total population 16 5,292  3.0 100.0 100.0
Colonization+ 14 1,029 13.6  19.4  87.5
Colonization-  2 4,263  0.5  80.7  12.5
Risk factors+ 11 1,311  8.4  24.7  68.8
Risk factors-  5 3,981  1.3  75.2  31.3
Colonization+ 10   245 40.8   4.6  62.5
Risk factors+
Colonization+  4   784  5.1  14.8  25.0
Risk factors-
Colonization-  1 1,066  0.9  20.0   6.2
Risk factors+
Colonization-  1 3,197  0.3  60.0   6.2
Risk factors-
*Colonization assessed by prenatal rectovaginal cultures. Risk factors defined as rupture of
membranes >12 hours, <37 weeks’ gestation, or intrapartum temperature >99.5 F (>37.5 C).
“+” refers to present; “-” refers to absent.
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Several vaccines designed to induce antibodies against the polysaccharide capsule
of GBS are being developed (39 ). These vaccines can potentially be used to prevent
GBS disease in nonpregnant adults as well. The potential impact of effective vaccines
may be limited because of reduced transplacental transport of protective antibody
before 32–34 weeks’ gestation and because of possible difficulty in making the vac-
cine available to pregnant women.
Chemoprophylaxis
Efficacy Studies
Administering antimicrobial agents to pregnant women before the onset of labor or
rupture of membranes is not likely to prevent neonatal GBS disease; however, some
early studies have indicated that maternal colonization might be reduced by this
method (40,41 ). In one study, asymptomatic pregnant women colonized with GBS
were given oral antimicrobial drugs for 1 week during the third trimester; more than
30% of those treated were still colonized at delivery, and no substantial difference was
observed in carriage of the organism at delivery between treated and untreated
groups (42 ). Another study indicated that nearly 70% of colonized women who were
treated for 12–14 days during the third trimester were colonized 3 weeks later and
again at delivery even when their sex partners also had been treated (43 ).
Postnatal chemoprophylaxis with intramuscular penicillin administered to infants
just after birth also has been studied. Only one prospective, randomized, controlled
study has been published in which blood cultures were collected from all newborns
before chemoprophylaxis was conducted (44 ). In this study, in which only low-
birth-weight infants were observed, no differences were observed between treated
and untreated groups in either the incidence of early- or late-onset GBS disease or in
mortality. Another study suggested that postnatal chemoprophylaxis with penicillin
may decrease neonatal illness caused by GBS (45,46 ). However, no significant effect
on overall mortality was observed, and mortality associated with penicillin-resistant
pathogens was higher in the penicillin-treated group than in the control group
(1.0 versus 0.4 deaths per 1,000 live births, p=0.06) (46 ). Because the majority of neo-
natal GBS infections are acquired in utero, antimicrobial agents administered to
neonates, although useful for treatment, are unlikely to prevent the majority of GBS
disease.
Intrapartum chemoprophylaxis (i.e., administration of antimicrobial agents after
onset of labor or membrane rupture but before delivery) is the most likely method of
preventing both early-onset disease and maternal illness resulting from GBS; several
antimicrobial regimens have been used for intrapartum chemoprophylaxis (Table 2).
Several studies have indicated that intrapartum chemoprophylaxis decreases
neonatal colonization (47–51 ) and early-onset invasive disease (50–53 ) when admin-
istered to unselected pregnant women colonized with GBS (Table 3).
Other studies have examined the use of intrapartum chemoprophylaxis for se-
lected women colonized with GBS who were at increased risk  for delivering an infant
who had GBS disease. The only prospective, randomized, controlled clinical trial in
which this approach was used focused on pregnant women colonized with GBS who
experienced either preterm labor or membrane rupture (at <37 weeks’ gestation) or
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prolonged rupture of membranes (>12 hours before delivery) (54 ). In a preliminary
study of the obstetric population in the same community, the incidence of early-onset
GBS disease in this high-risk group was eightfold greater than among colonized
women without any of these risk factors and 45-fold greater than among women with
these risk factors who were not colonized (Table 1) (20,55,56 ).
In the intrapartum chemoprophylaxis trial, colonized mothers with preterm labor or
whose membranes ruptured >12 hours before delivery were randomly selected to re-
ceive either intravenous ampicillin or no chemoprophylaxis. Infants born to mothers
in the treatment (85 infants) and control groups (79 infants) differed substantially with
respect to neonatal colonization (9% versus 51%, p<0.001) and early-onset invasive
disease (0% versus 6%, p<0.02). Postpartum maternal febrile illness also was substan-
tially reduced in the treatment group (p<0.04). Researchers estimated that this
strategy could prevent at least 50% of the early-onset GBS infections in their patient
population (54 ).
Other studies also have documented the protective efficacy of intrapartum chemo-
prophylaxis administered to GBS carriers in certain high-risk groups (e.g., women
with heavy genital colonization [57,58 ] and with rupture of membranes at ≤34 weeks’
gestation and >12 hours before labor onset [59 ]). The published studies of the efficacy
of intrapartum chemoprophylaxis are summarized (Table 3). A recent meta-analysis of
seven trials, which included studies of carriers with and without risk factors, estimated
a 30-fold reduction in early-onset GBS disease with intrapartum chemoprophylaxis
(60 ). Other investigators have argued that, because of the heterogeneity of therapeu-
tic interventions and flaws in trial methods, combining results of GBS chemo-
prophylaxis trials is inappropriate (61 ).
TABLE 2. Summary of antimicrobial regimens used for studies of intrapartum
chemoprophylaxis for group B streptococcal (GBS) disease
Agent Dose and schedule* Comments†
Ampicillin (47 ) 500 mg IV every 6 hrs 30/34 received only one dose
before delivery
Ampicillin (52 ) 500 mg IV Administered every 6 hrs
Benzyl penicillin (48 ) 600 mg IM every 8 hrs Erythromycin 100 mg IM for
women allergic to penicillin
Ampicillin (50 ) 500 mg IV every 6 hrs 46/57 received only one dose
before delivery
Penicillin (53 ) 1 mU IV every 6 hrs
Ampicillin (54 ) 2 g IV load, then 1 g IV every
4 hrs
Mean duration of prophylaxis 5.4
hrs
Penicillin G (58 ) 5 mU IV every 6 hrs If labor lasted 18 hrs, then
penicillin V 1 mU should be
administered orally every 8 hrs
after initial IV therapy
Ampicillin (59 ) 1 g IV every 6 hrs
Ampicillin (57 ) 1 g IV every 6 hrs Ampicillin levels measured in
eight mother-infant pairs
*IV = intravenous; IM = intramuscular.
†mU = million units.
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Identification of Carriers
Most of the studies of intrapartum chemoprophylaxis have been used to evaluate
its impact on subsets of women who had been identified as GBS carriers. Although
the GBS carriage rate in pregnancy does not change with trimester (12,14 ), the dura-
tion of carriage is unpredictable (14 ), and prenatal screening cultures will not
correctly identify all women with intrapartum GBS carriage. The later in pregnancy
that cultures are performed, the closer the correlation with intrapartum culture results.
However, scheduling routine cultures late in pregnancy means that some women
who deliver prematurely will not be screened for GBS. In one study, when selective
(antimicrobial-containing) broth medium was used and cultures were obtained from
both the vagina and anorectum, only 7.4% of women with a negative culture at
26–28 weeks were found to carry GBS at delivery (16 ). The same study indicated that
a single positive GBS culture during pregnancy was 67% predictive of a positive
culture at delivery; the estimated sensitivity and specificity were 70.0% and 90.4%,
respectively (16 ). Among 26 women whose prenatal cultures were obtained ≤5 weeks
before delivery, there was 100% concordance with intrapartum culture status (i.e., no
TABLE 3. Summary of trials employing intrapartum chemoprophylaxis for prevention





Neonatal colonization Early-onset disease
IC§ No IC P value IC No IC P value
R (47 )
Random
I 0/34 14/24 0.001 0/34 0/24 NA¶
P/R (52 )
Nonrandom
I 4/57 62/136 <0.01 0/57 9/136 0.06
P (48 )
Random
PC 0/38 17/49 0.001 ND ND NA
P (50 )
Random
I or PC 2/60 24/65 <0.01 0/60 3/65 0.14
P (53 )
Nonrandom












Pre/PROM 5/82 102/233 <0.01 0/82 7/233 0.02
P (58 )
Random








PPROM ND ND NA 0/7 7/11 0.01
P (57 )
Random
Light PC 0/98 35/98 <0.01 0/98 0/98 NA
Heavy PC 0/37 24/30 <0.01 0/37 3/30 0.09
*R=retrospective; P/R=prospective case selection, retrospective control selection; P=prospective.
†I=intrapartum colonization; PC=prenatal colonization; Pre/PROM=preterm labor (<37 weeks’
gestation) or prolonged rupture of membranes (>12 hours); PPROM="preterm premature rup-
ture of membranes" ( i.e., rupture of membranes at ≤34 weeks’ gestation and >12 hours before
onset of labor).
§IC=Intrapartum chemoprophylaxis; ND=not done.
¶NA=not applicable.
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false-negative or false-positive prenatal cultures) (16 ). Data from follow-up of more
than 5,000 deliveries by women who had had prenatal cultures for GBS indicated that
14 (88%) of the 16 infants who developed early-onset GBS disease were born to moth-
ers who were detected prenatally as carriers (56 ).
Optimal identification of GBS carriers is dependent on technique. The correlation of
prenatal culture results with intrapartum GBS carriage is likely to be reduced substan-
tially when screening does not incorporate appropriate culture sites (i.e., rectum and
vaginal introitus), timing (as close to delivery as feasible), and culture medium (selec-
tive broth). Because cultures of specimens from the vagina and rectum are more
sensitive than specimens from the cervix, (13 ), pelvic examination or visualization of
the cervix by speculum examination should not be performed for collection of screen-
ing cultures. Appropriate broth media are commercially available (e.g., SBM broth or
Lim broth). When a transport medium (e.g., Amies’ medium) is used, group B strepto-
cocci from rectovaginal swabs will survive at room temperatures for up to 96 hours,
permitting shipment from satellite clinics to a central microbiology laboratory.
Selection Criteria
Because of the findings of a randomized clinical trial, investigators recommended
intrapartum chemoprophylaxis for those women identified through prenatal cultures
as GBS carriers who subsequently develop one of the following signs: rupture of
membranes >12 hours before delivery, onset of labor or membrane rupture at
<37 weeks’ gestation, or intrapartum fever (temperature >99.5 F [>37.5 C]) (54 ). The
American Academy of Pediatrics (AAP) supports the use of this strategy and added
the following indications for intrapartum chemoprophylaxis: previous delivery of an
infant with GBS disease and multiple-gestation pregnancy in a GBS carrier (62 ).
In another report, investigators proposed an approach to GBS prevention that fo-
cused on prevention of disease associated with premature birth (63 ). That proposal
suggested administering intrapartum antimicrobial agents to women with preterm
labor or preterm rupture of membranes who were either colonized with GBS or whose
colonization status was unknown. However, strategies designed to prevent infection
only in preterm deliveries would have limited impact nationwide because <30% of all
infants with GBS disease are preterm (2 ).
A pragmatic approach to determining the need for antimicrobial prophylaxis was
advocated by the American College of Obstetricians and Gynecologists (64,65 ). This
strategy consists of using intrapartum antimicrobial agents for all women with one or
more of the following conditions: preterm labor (at <37 weeks’ gestation), premature
rupture of membranes (at <37 weeks’ gestation), prolonged rupture of membranes
(i.e., >18 hours before delivery), previous child affected by symptomatic GBS infec-
tion, or maternal fever during labor (65 ). This approach is less complex than protocols
requiring either prenatal or intrapartum identification of GBS carriage; however, its
efficacy against disease has not been evaluated in the controlled clinical trial setting,
nor has the impact of the strategy on disease been measured in routine clinical prac-
tice.
In Australia, researchers evaluated a strategy that recommended intrapartum peni-
cillin prophylaxis for all women identified as GBS carriers through prenatal cultures
collected at 32 weeks’ gestation (53 ). Although the study was not a randomized trial,
data from the study indicated a substantially lower incidence of early-onset GBS
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disease among the 30,197 women in the screened population compared with the
26,915 deliveries in the population that had no prenatal screening (p=0.04) (53 ).
Clinical trials have not been conducted that directly compare the efficacy of the
suggested prevention strategies. Conducting a study designed to find a statistically
significant difference in efficacy may not be feasible; a recent article estimated that
100,000 women would be required for each study group of a randomized prospective
trial comparing the efficacy of universal screening and selective intrapartum chemo-
prophylaxis with treatment based on risk factors alone (66 ). This limitation is reflected
in a recent national consensus statement by the Society of Obstetricians and Gynae-
cologists of Canada and the Canadian Paediatric Society, which recommended use of
either universal screening and selective intrapartum chemoprophylaxis or prophy-
laxis based on risk factors alone; the statement underscored the need for further
prevention research (67 ).
A combination of the features of a screening-based strategy and a strategy fo-
cused on prematurity offers a comprehensive approach to perinatal GBS prevention.
This combination strategy relies on detection of GBS by rectovaginal cultures col-
lected at 35–37 weeks’ gestation; because some preterm deliveries will occur before
culture results are available, the strategy also provides for intrapartum chemoprophy-
laxis for women who begin labor and/or membrane rupture before 37 completed
weeks’ gestation (i.e., unless results of the GBS culture are already available and are
negative). Antibiotics would be offered intrapartum to all GBS carriers and to women
at <37 weeks’ gestation whose culture status is unknown. For women with rupture of
membranes at <37 weeks who are not in labor, obstetric-care providers may choose
either to begin antimicrobial prophylaxis until cultures are completed and negative or
to delay beginning antimicrobial prophylaxis until a positive culture is identified. Data
regarding which of these approaches is the most effective are not available. For
women at ≥37 weeks’ gestation, if antenatal GBS culture status is unknown, antibiot-
ics would be given if intrapartum fever is present or if membrane rupture has been
>18 hours. This precise strategy has not been directly evaluated in clinical trials, al-
though treatment of all GBS carriers identified through screening at 32 weeks’
gestation  was evaluated in a trial in Australia (53 ). Data from another study demon-
strated that the closer to delivery screening cultures are collected, the higher the
predictive value of the test (16 ). In addition, this combination strategy and 18 other
strategies have been evaluated by decision analysis (68 ); results indicate that the
combination strategy would require intrapartum antimicrobial prophylaxis in 26.7% of
deliveries and would prevent approximately 86% of of the cases of early-onset dis-
ease. Comparative estimates for other strategies also are provided (Table 4).
Adverse Effects
Because a substantial proportion of pregnant women are colonized with GBS, ad-
ministration of intrapartum chemoprophylaxis to all GBS carriers may cause an
unacceptably high number of adverse reactions. Administering intrapartum antimi-
crobial agents to all women who are GBS carriers could result in approximately
10 deaths per year from anaphylaxis, assuming a GBS colonization rate of 25%, 4 mil-
lion deliveries in the United States annually, and a rate of fatal anaphylaxis to
penicillin of 0.001% (69 ). Another 0.7%–10% of women to whom prophylaxis is
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administered is expected to have less severe reactions (70 ). Severe complications can
occur in the fetus even when maternal anaphylaxis is not life threatening (71 ).
Widespread antimicrobial use also increases the risk for emergence of
antimicrobial-resistant organisms. Infections with penicillin-tolerant GBS have been
described (72–74 ), but GBS isolates have not developed clinically important resis-
tance to penicillin. Development of antimicrobial resistance in other peripartum
pathogens is a greater threat. In one study, investigators reported four episodes of
adverse perinatal outcome caused by antimicrobial-resistant Enterobacteriaceae
among women treated with ampicillin or amoxicillin for premature rupture of mem-
branes (75 ).
Restricting antimicrobial agents to selected populations at increased risk for de-
livering a newborn with GBS disease would decrease the likelihood of adverse
reactions and antimicrobial-resistant infections. Administering intrapartum ampicillin
to women identified prenatally as GBS carriers who have rupture of membranes for
>12 hours, labor or membrane rupture at <37 weeks’ gestation, or intrapartum fever
(temperature >99.5 F [>37.5 C]) would have required administering antimicrobial
agents to 4.6% of the obstetric population served by one urban hospital (54 ). In an-
other approach, administering antimicrobial agents to women with either labor or
membrane rupture at <37 weeks’ gestation who are intrapartum carriers of GBS or
whose GBS status is unknown was estimated to require prophylaxis for 8.9% of partu-
rients (63 ). Strategies that treat all GBS carriers (53 ) or all women with obstetric risk
factors (e.g., prolonged membrane rupture and prematurity) (64 ) are estimated to
require administering antimicrobial agents in a substantially higher proportion of
deliveries.
TABLE 4. Estimated impact of several strategies for the use of intrapartum
antimicrobial prophylaxis (IAP) against early-onset group B streptococcal (GBS)








Prenatal culture at 35–37 weeks’
gestation; IAP for preterm deliveries
and all GBS carriers*
86.0 26.7
Prenatal culture at 26–28 weeks’
gestation; IAP for GBS carriers who
develop intrapartum risk factors
(e.g., fever, prolonged rupture of
membranes, <37 weeks’ gestation) (54 )
50.7  3.4†
No prenatal cultures; IAP for all women
with intrapartum risk factors
(e.g., fever, prolonged rupture of
membranes, <37 weeks’ gestation)¶
68.8 18.3§
*Combination strategy; refer to Figure 1.
†Percentage was estimated for a hypothetical population (68 ); actual proportion of deliveries
among women who had prenatal screening cultures positive for GBS and who also developed
intrapartum risk factors was 4.6% (20 ).
§Percentage was estimated for a hypothetical population (68 ); actual proportion of deliveries
among women who had intrapartum risk factors was 24.7% (20 ).
¶Empiric strategy suggested by the American College of Obstetricians and Gynecologists in
1993 (64,65 ); refer to Figure 2.
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Penicillin G may be preferable to ampicillin for routine prophylaxis (76 ). Ampicillin
and penicillin G have similar activity against GBS, and both cross the placenta and
achieve bactericidal levels in fetal tissues. However, ampicillin has a broader spectrum
of antimicrobial activity than penicillin; thus, widespread prophylaxis with ampicillin
may be more likely to lead to selection of resistant organisms than would widespread
use of penicillin (76 ).
Implementation of Chemoprophylaxis
Despite the encouraging results of efficacy studies, routine GBS screening and
selective intrapartum chemoprophylaxis have not been widely adopted in the obstet-
ric community (65,77 ). Practical problems include logistic concerns related to
screening for GBS colonization and concern about the cost-effectiveness of imple-
menting chemoprophylaxis.
A strategy based on detecting colonization by prenatal screening and using these
results to guide selective intrapartum chemoprophylaxis would not be effective for
women who are not receiving prenatal care or whose prenatal records are not avail-
able to health-care providers at the time of delivery. Ideally, GBS carriage would be
determined at the time of labor onset or at rupture of membranes. However, because
identification of GBS by culture takes 24–48 hours, intrapartum culture results would
not be available in time for intervention in most deliveries. Rapid detection of GBS
antigen from vaginal specimens may identify GBS carriers when prenatal screening is
not available (78 ). Although rapid tests for detection of GBS are specific and many
recently developed tests can be performed in <1 hour, the sensitivity of rapid-detec-
tion tests has been variable and, often, unacceptably low (15%–74%) (78 ). Some
rapid-detection kits are sensitive for detecting women who are heavily colonized.
Three studies have confirmed the efficacy of intrapartum chemoprophylaxis adminis-
tered to women identified by rapid-detection techniques as GBS carriers (57–59 ).
However, because many infants with neonatal GBS disease are born to women who
are lightly colonized (59,79 ), using currently available rapid-detection techniques to
identify women for prophylaxis would probably prevent only a minority of GBS cases.
The cost-effectiveness of selective intrapartum chemoprophylaxis for the preven-
tion of GBS disease has been studied by using population-based rates of disease (80 ).
The approach evaluated by two investigators (54 ) and later endorsed by AAP (62 )
was demonstrated to be cost-effective at the current rates of disease (80 ). The cost
per case prevented (<$35,000) was similar to that associated with maternal screening
and intervention programs for other perinatal diseases (e.g., congenital syphilis) (81 ).
Data from four other studies also have suggested that selective intrapartum chemo-
prophylaxis is cost-effective for the prevention of neonatal GBS disease (56,68,82,83 ).
In particular, one study evaluated the combination strategy (i.e., prophylaxis for all
women with preterm membrane rupture or labor whose culture status is unknown
and for all GBS carriers identified through cultures obtained late in the pregnancy);
this combination strategy was cost saving and was among the least expensive of
18 potential preventive strategies (68 ).
Implementation of chemoprophylaxis is limited by two additional problems. First,
clinicians have been concerned about adopting a strategy that inevitably will have fail-
ures (64 ). This concern may be influenced by the complexity of communicating
risk information regarding GBS to women during pregnancy or by medicolegal
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considerations. Previous efforts to promote use of intrapartum chemoprophylaxis for
only those GBS carriers who develop intrapartum complications (e.g., longer duration
of membrane rupture, fever, or <37 weeks’ gestation) appear to have been poorly
accepted by both clinicians and patients. Some clinicians and patient groups have
advocated informed consent for women who are GBS carriers. For example, women
colonized with GBS would be informed of their risk for early-onset GBS disease
(approximately 1 in 200). Also, the potential risks of intrapartum penicillin would be
described (mild allergic reaction: approximately 1 in 10; anaphylaxis: approximately
1 in 10,000; and fatal anaphylaxis: approximately 1 in 100,000). Thus, patients could
make an informed decision regarding intrapartum antibiotics. In instances in which
this approach has been applied, few women choose not to receive antibiotics during
labor.
A second problem is that increasing intrapartum antimicrobial use may have a sub-
stantial impact on clinical management of the newborn (84,85 ). Some pediatricians
routinely perform additional diagnostic tests on all infants whose mothers received
intrapartum antimicrobial agents or observe these infants longer, leading to pro-
longed hospital stays for many newborns who are low risk for GBS disease (84 ). The
decision of how to manage newborns whose mothers received intrapartum antimicro-
bial agents can be based on clinical manifestations, the infant’s estimated gestational
age, and the adequacy of intrapartum antibiotics (62 ). An algorithm for evaluating
and managing infants after administration of maternal antibiotics has been developed
as an empiric guide; however, clinical evaluation of alternative approaches remains
appropriate at this time.
Some of the challenges of instituting a prevention strategy are illustrated in two
recent reports. In the first report, investigators initiated selective intrapartum chemo-
prophylaxis in their hospital in response to an increased rate of early-onset GBS
disease (85 ). They enrolled 2,040 women, 332 (16.3%) of whom were colonized with
GBS. Among women colonized at delivery, 122 (37%) had at least one obstetric risk
factor and, according to the hospital’s protocol, should have received intrapartum
chemoprophylaxis. The circumstances of 16 (13%) women who did not receive intra-
partum chemoprophylaxis illustrate some limitations of this strategy; these women
did not receive intrapartum antimicrobial drugs because they either delivered <1 hour
after arriving at the hospital (n=9), had had no prenatal care (n=3), or had had a nega-
tive prenatal culture but had a positive culture at delivery (n=4). Intrapartum
chemoprophylaxis was not administered to an additional 17 (14%) women because
protocol was not followed. Eleven infants had early-onset GBS disease; two had re-
ceived one dose of intrapartum chemoprophylaxis and were asymptomatic; and nine
were born to carriers with risk factors who did not receive intrapartum chemoprophy-
laxis. No affected infants were born to colonized women without risk factors or to
women whose prenatal screening cultures were negative for GBS. One woman who
received intrapartum chemoprophylaxis developed a rash and transient hypotension
and was delivered by cesarean section because of transient fetal bradycardia. The
study suggested that selective intrapartum chemoprophylaxis was effective in pre-
venting early-onset GBS disease, that the infants of colonized women without labor
complications are at low risk for disease, and that administering intrapartum antimi-
crobial agents is not without risks.
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The second report illustrates that a prevention strategy employing selective intra-
partum chemoprophylaxis is not easily implemented (86 ). In this study, which was
conducted in an academic setting, 114 (80.3%) of 142 women who had positive GBS
screening cultures and who developed risk factors at delivery received intrapartum
antimicrobial drugs. Reasons for failing to receive appropriate treatment included fail-
ure to follow protocol, marginal indications for chemoprophylaxis, or patient refusal.
Early results of the study suggest that institution of the protocol was associated with
a downward trend in the rate of disease.
DISCUSSION
Group B streptococcal disease continues to be a major cause of illness and
death among newborns despite clinical advances in the last two decades. Major risk
factors for early-onset neonatal GBS disease include maternal GBS colonization,
longer duration of membrane rupture, intrapartum fever, <37 weeks’ gestation, GBS
bacteriuria during pregnancy, and previous delivery of an infant who had GBS disease
(6,21,25,27 ). A substantial number of cases of early-onset neonatal GBS disease can
be prevented by administering prophylactic antimicrobial agents during labor (56 ).
Furthermore, obtaining specimens from the lower vagina and rectum during the third
trimester for culture in selective broth media will identify the vast majority of women
who are colonized with GBS at delivery. Increasing evidence suggests that treating
GBS-infected newborns is more costly than preventing the infection and that well-
implemented prevention programs can substantially reduce illness and death result-
ing from GBS disease (56,68,80,82,83 ). Any prevention program for GBS must be
implemented carefully. For example, failure to use optimal culture methods can com-
promise the effectiveness of screening strategies. A recent survey of obstetric-care
providers in Georgia identified several barriers to effective prevention activities. For
example, only 9% of providers who obtained screening cultures followed recom-
mended procedures and 32% administered antimicrobial agents prenatally when
carriage was detected even though 93% of providers stated they knew such treatment
to be ineffective (87 ).
An optimal prevention strategy currently is a combination of routine prenatal
screening for GBS colonization late in pregnancy and empiric management of those
preterm deliveries that occur before the GBS culture is available. This approach
includes collecting rectovaginal cultures at 35–37 weeks’ gestation and offering intra-
partum treatment to all carriers. Because some preterm deliveries occur before
culture results are available, the strategy also provides for intrapartum chemoprophy-
laxis for women who begin labor and/or membrane rupture before 37 completed
weeks’ gestation (unless results of the GBS culture are already available and are nega-
tive).
Criticism of previous screening-based strategies has included concerns regarding
the predictive value of prenatal cultures, the ethical and legal difficulties inherent in
withholding intrapartum antibiotics from GBS carriers without risk factors, and the
pressure experienced by clinicians to respond to antenatal GBS carriage results
by treating with oral antimicrobial agents remote from delivery. Critics of empiric
approaches have been concerned that despite use of intrapartum antimicrobial
prophylaxis in a substantial proportion of deliveries, the strategy does not prevent
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the 25% of all early-onset GBS cases that occur in GBS carriers without risk factors.
Further, empiric approaches do not address the strong preference of some patients
and providers for prenatal screening cultures.
Rationale for Screening-Based Approach to Prevention
The combination of late prenatal-screening cultures and empiric management of-
fers several potential advantages over exclusive reliance on either a screening-based
approach or an empiric approach. Because the combination strategy schedules collec-
tion of a GBS culture at 35–37 weeks’ gestation, the concordance of prenatal and
intrapartum GBS carriage status will be high. Thus, false-negative prenatal culture
results will be minimized (i.e., few women with negative cultures at 35–37 weeks’ ges-
tation will become colonized with GBS by the time of delivery), and nearly all women
identified antenatally as carriers will still be carrying the organism at delivery, poten-
tially justifying exposing this group to adverse effects associated with antibiotics.
Even women who begin prenatal care late in gestation should be eligible for late
screening. By avoiding collection of cultures earlier in gestation, this strategy should
reduce pressure on clinicians to treat GBS carriage antenatally. Because all GBS carri-
ers will be offered intrapartum chemoprophylaxis, clinicians will not need to wait
for the development of intrapartum risk factors in a GBS carrier (e.g., duration of
membrane rupture >18 hours or intrapartum fever). Intrapartum prophylaxis for most
women can therefore begin earlier, so that most GBS carriers will be administered
antimicrobial agents >4 hours before delivery or in time for adequate antibiotic levels
to be reached in amniotic fluid. In one analysis, the combination of late prenatal
screening and intrapartum prophylaxis of carriers and preterm deliveries was
estimated to prevent approximately 86% of early-onset disease, was cost-saving
compared with no intervention, and was among the least expensive of 18 potential
preventive strategies (68 ).
Large-scale clinical experience with the combination approach previously
described is not yet available, although the strategy has been applied in several insti-
tutions. The theoretical advantages of this approach address most concerns that have
been raised regarding the prevention strategies previously considered. Although an-
timicrobial prophylaxis will be used in a high proportion of deliveries, some clinicians
and patients have found selective approaches (e.g., treating only carriers with risk fac-
tors) unacceptable, because treatment is withheld from a group of women with
moderately increased risk of GBS disease—GBS carriers without intrapartum risk fac-
tors. Assessment of the current situation suggests that any prevention program that is
acceptable to both clinicians and their patients will involve using antimicrobial pro-
phylaxis in a substantial proportion of deliveries; thus, the strategy that directs use of
these antimicrobial agents to women at the highest risk for GBS disease seems rea-
sonable. Communication mechanisms and information systems should be developed
and monitored to ensure that prenatal culture results are available at the time and
place of delivery.
Research into Enhancing Prevention
A program combining late prenatal screening for GBS with empiric treatment of
women with preterm deliveries is not a permanent solution to the problem of neonatal
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GBS disease, although it may be a reasonable option that is available now. A more
sensitive rapid-screening test for GBS that could accurately detect women who carry
GBS at the time of delivery would obviate the need for prenatal screening. Sensitive
intrapartum testing also would permit detection of GBS carriage among women who
did not receive adequate prenatal care. Because an intrapartum test might detect a
higher proportion of women who carry the organism at delivery and will not detect
women who only carry the organism earlier in pregnancy, intrapartum use of a sensi-
tive rapid-detection test could make a prevention program simpler and more efficient.
An adequate rapid-detection test must be a) sensitive (e.g., 85%–90% compared with
culture in selective broth media); b) rapid (results available to clinicians in time for
antibiotics to be given before delivery); and c) convenient (for integration into routine
laboratory use). Even a highly sensitive rapid-detection test would not be adequate if
results were not available to clinicians 24 hours a day, 7 days a week. Development of
a vaccine against GBS that is highly immunogenic in women and permits transplacen-
tal transfer of protection to the fetus also would eliminate the need for prenatal
screening and could potentially address the problem of late-onset GBS disease, which
intrapartum antimicrobial agents do not prevent.
Surveillance and Evaluation
Because incidence may vary widely, state or local health departments or groups of
affiliated hospitals should consider either establishing surveillance systems for neo-
natal GBS disease or reviewing data from existing systems to identify the current
magnitude of disease and gain further information for evaluating the effectiveness of
prevention measures. In hospital settings, prevention programs should monitor the
occurrence of adverse reactions to chemoprophylaxis, the emergence of perinatal in-
fections caused by antimicrobial-resistant organisms, and the impact of obstetric
antimicrobial use on pediatric management protocols.
RECOMMENDATIONS
Enhanced communication among personnel in multiple disciplines is needed to
ensure that programs for prevention of GBS disease succeed. Open communication
between clinicians and patients is a critical component of GBS disease prevention. An
informational brochure for pregnant women on GBS is available through CDC (Child-
hood and Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases,
National Center for Infectious Diseases, Mailstop C09, Atlanta, GA 30333; Internet
address: http://www.cdc.gov/ncidod/diseases/bacter/strep_b.htm. The following rec-
ommendations for the prevention of GBS disease will need periodic reappraisal to
incorporate advances in technology or other refinements in prevention strategies.
1. Obstetric-care practitioners, in conjunction with supporting laboratories and labor
and delivery facilities, should adopt a strategy for the prevention of early-onset
GBS disease. Patients should be informed regarding the GBS prevention strategy.
2. Regardless of which preventive strategy is used, a) women with symptomatic or
asymptomatic GBS bacteriuria detected during pregnancy should be treated at the
time of diagnosis; because such women are usually heavily colonized with GBS,
they should also receive intrapartum chemoprophylaxis; and b) women who
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previously have given birth to an infant with GBS disease should receive intrapar-
tum chemoprophylaxis; prenatal screening is not necessary for these women.
3. Until further data become available to define the most effective strategy, the follow-
ing two approaches are appropriate:
Screening-Based Approach. All pregnant women should be screened at 35–37
weeks’ gestation for anogenital GBS colonization (Figure 1). Patients should be in-
formed of screening results and of potential benefits and risks of intrapartum
antimicrobial prophylaxis for GBS carriers. Information systems should be devel-
oped and monitored to ensure that prenatal culture results are available at the time
and place of delivery. Intrapartum chemoprophylaxis should be offered to all preg-
nant women identified as GBS carriers by culture at 35–37 weeks’ gestation.
1) If the result of GBS culture is not known at the time of labor, intrapartum
antimicrobial prophylaxis should be administered if one of the following
risk factors is present: <37 weeks’ gestation, duration of membrane rup-
ture ≥18 hours, or temperature ≥100.4 F (≥38.0 C).
Delivery at <37 weeks’ gestation*
Risk factors:
Previous infant who had invasive GBS disease
GBS bacteriuria during this pregnancy
Yes
No
Collect rectal and vaginal swab for GBS culture
at 35-37 weeks’ gestation








>100.4 F (>38.0 C)
Membrane rupture >18 hours
No








*If membranes ruptured at <37 weeks’ gestation, and the mother has not begun labor, collect
group B streptococcal culture and either a) administer antibiotics until cultures are completed
and the results are negative or b) begin antibiotics only when positive cultures are available.
No prophylaxis is needed if culture obtained at 35–37 weeks’ gestation was negative.
†Broader spectrum antibiotics may be considered at the physician’s discretion, based on clinical
indications.
FIGURE 1. Algorithm for prevention of early-onset group B streptococcal (GBS)
disease in neonates, using prenatal screening at 35–37 weeks’ gestation
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2) Culture techniques that maximize the likelihood of GBS recovery should
be used. Because lower vaginal and rectal cultures are recommended,
cultures should not be collected by speculum examination. The optimal
method for GBS screening is collection of a single standard culture swab
or two separate swabs of the distal vagina and anorectum. Swabs may be
placed in a transport medium (e.g., Amies’) if the microbiology laboratory
is offsite. The sample should be identified for the laboratory as specifically
for GBS culture. Specimens should be inoculated into selective broth me-
dium (either SBM broth or Lim broth), followed by overnight incubation
and then subcultured onto solid blood agar medium. In this screening cul-
ture, there is no need for the laboratory to culture for other organisms. A
laboratory procedure to maximize recovery of GBS is detailed (Box 1).
3) Laboratories should report results (both positive and negative) to both the
anticipated site of delivery and the health-care provider who ordered the
test. Ideally, laboratories that perform GBS cultures will ensure that clini-
cians have continuous access (i.e., 24 hours a day, 7 days a week) to
culture results.
1. Obtain one or two swabs of the vaginal introitus and anorectum. Cervi-
cal cultures are not acceptable; a speculum should not be used for
culture collection.
2. Place the swabs into a transport medium. The swabs in a transport me-
dium will maintain GBS viability for up to 4 days at room temperature
or under refrigeration. Appropriate nonnutritive moist swab transport
systems (e.g. Amies’) are commercially available.
3. Remove the swabs from the transport medium and inoculate both
swabs together into selective broth medium. Todd-Hewitt broth sup-
plemented with either colistin (10 g/mL) and nalidixic acid (15 g/mL) or
with gentamicin (8 g/mL) and nalidixic acid (15 g/mL) may be used;
appropriate commercially available options include Lim or SBM broth.
 
4. Incubate selective broth for 18–24 hrs. Subculture the broth to sheep
blood agar plate.
5. Inspect and identify organisms suggestive of GBS (beta hemolytic
or nonhemolytic, gram-positive and catalase negative). If GBS is not
identified after incubation for 18–24 hrs on sheep blood agar plate, re-
incubate and inspect at 48 hrs to identify suspected organisms.
6. Various slide agglutination tests or other tests for GBS antigen detec-
tion (e.g., genetic probe or fluorescent antibody) may be used for
specific identification, or the CAMP test may be employed for pre-
sumptive identification. 
BOX 1. Procedure for collecting and processing clinical specimens for culture of group
B Streptococcus 
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4) Oral antimicrobial agents should not be used to treat women who are
found to be colonized with GBS during prenatal screening. Such treatment
is not effective in eliminating carriage or preventing neonatal disease.
Risk-Factor Approach. A prophylaxis strategy based on the presence of intrapar-
tum risk factors alone (e.g., <37 weeks’ gestation, duration of membrane rupture
≥18 hours, or temperature ≥100.4 F [≥38.0 C]) is an acceptable alternative (Figure 2).
4. For intrapartum chemoprophylaxis, intravenous penicillin G (5 mU initially and
then 2.5 mU every 4 hours) should be administered until delivery (Box 2). Intrave-
nous ampicillin (2 g initially and then 1 g every 4 hours until delivery) is an
acceptable alternative to penicillin G, but penicillin G is preferred because it has a
narrow spectrum and thus is less likely to select for antibiotic resistant organisms.
Clindamycin or erythromycin may be used for women allergic to penicillin, al-
though the efficacy of these drugs for GBS disease prevention has not been
measured in controlled trials. (Note: Penicillin G does not need to be administered
to women who have clinical diagnoses of amnionitis and who are receiving other
treatment regimens that include agents active against streptococci [e.g., ampicillin
or clindamycin].)
5. Routine use of prophylactic antimicrobial agents for infants born to mothers who
received intrapartum prophylaxis is not recommended. However, therapeutic use
of these agents is appropriate for those infants suspected clinically of having sep-
sis. Additional research is needed to determine algorithms for management of
infants born to mothers who receive intrapartum antimicrobial prophylaxis. One
algorithm for empiric management of these newborns is provided (Figure 3). Other
management approaches, developed by individual physicians or institutions, may
be appropriate alternatives.
6. Local and state public health agencies, in conjunction with appropriate groups of
hospitals, should consider establishing surveillance to monitor the incidence of
neonatal GBS disease, occurrence of adverse reactions to antimicrobial prophy-
laxis, and the emergence of perinatal infections caused by penicillin-resistant
organisms.
Investigations designed to evaluate and compare these two strategies and others
are needed. Such studies will require the participation of multiple institutions and
should evaluate multiple outcomes (e.g., perinatal GBS infections, adverse reactions
to antimicrobial prophylaxis, and perinatal infections caused by penicillin-resistant
organisms). Characterization of protocol failures may contribute to improvement of
future prevention strategies.
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Recommended Penicillin G, 5 mU IV 
load, then 2.5 mUs IV every
4 hrs until delivery
Alternative Ampicillin, 2 g IV load, then 1 g 
IV every 4 hrs until delivery
If penicillin-allergic
 Recommended Clindamycin, 900 mg IV every 8 hrs
until delivery
 Alternative Erythromycin, 500 mg IV every 6 hrs until delivery
*Note: If patient is receiving treatment for amnionitis with an antimicrobial agent active against
group B streptocci (e.g., ampicillin, penicillin, clindamycin, or erythromycin), additional pro-
phylactic antibiotics are not needed.
BOX 2. Recommended regimens for intrapartum antimicrobial prophylaxis for
perinatal group B streptococcal disease
Previously delivered infant
who had invasive GBS disease
GBS bacteriuria during this pregnancy
Delivery at <37 weeks’ gestation*
Yes
No




Duration of ruptured membranes >18 hours
Are any of the following risk factors present?





*If membranes ruptured at <37 weeks’ gestation, and the mother has not begun labor, collect
group B streptococcal culture and either a) administer antibiotics until cultures are completed
and the results are negative or b) begin antibiotics only when positive cultures are available.
†Broader spectrum antibiotics may be considered at the physician’s discretion, based on clinical
indications.
FIGURE 2. Algorithm for prevention of early-onset of group B streptococcal (GBS)
disease in neonates, using risk factors
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**CBC and differential and a blood culture.
†† Does not allow early discharge.
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